Seeking Alpha

Adamis submits NDA for adrenaline product

  • Adamis Pharmaceuticals (ADMP) submits an NDA for its epinephrine pre-filled single dose syringe (1:1000; 0.3 mg) for the emergency treatment of allergic reactions (Type 1) including anaphylaxis. The company believes its product will be an attractive lower cost substitute versus the more-expensive auto-injectors.
Comments (2)
  • dramorgan
    , contributor
    Comments (55) | Send Message

    For anyone who wants an overview of NDA process.
    29 May, 09:11 AM Reply Like
  • wyattkap
    , contributor
    Comments (43) | Send Message
    MAJOR step in the right direction. AMAZING how few people care about this company. Been too quiet for too long I suppose. Doesn't take away from the massive valuation I see ahead of us. The buying opportunity just got a whole lot better.
    30 May, 04:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector